CNTY-308 / Century Therap - LARVOL DELTA

CNTY-308 and Other Preclinical Program (GlobeNewswire) - "Following successful completion of these IND-enabling studies and the receipt of requisite regulatory approval, Century plans to initiate clinical studies in 2026....Century is leveraging its deep expertise in selective iPSC differentiation in high-impact therapeutic areas."

New trial • Immunology

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) - "CNTY-308 on track to enter into IND-enabling studies in mid-2025: The company continues to expect to initiate Investigational New Drug (IND)-enabling studies with CNTY-308, a CD19-targeted CD4+/CD8+ ab CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases and malignancies, in mid-2025."

Preclinical • Immunology • Oncology

Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025 (GlobeNewswire) - "The event will feature discussion of CNTY-308, a CD19-targeted CAR-iT investigational cell therapy, CNTY-341, a CD19/CD22 dual-targeted CAR-iT investigational cell therapy, and the company’s first solid tumor CAR iT investigational program exploiting Nectin-4 CAR and other validated targets. Each of these programs is anchored by advanced iPSC-derived ’tunable’ CD4+/CD8+ ab T cells."

Clinical data • Oncology

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) - "Phase 1 CALiPSO-1 trial site expansion in United States and Europe: The first patient in our CALiPSO-1 Phase 1 trial in autoimmune diseases is enrolled and scheduled for dosing in March 2025. Five sites in the U.S. are actively screening patients and Century has increased resourcing for trial site activation and proficient recruitment. The company is also expanding the CALiPSO-1 clinical trial to include additional sites in select European countries and expects enrollment at those sites will initiate in the second half of 2025....CNTY-308 is being developed for B-cell mediated autoimmune diseases...The company expects to initiate IND-enabling studies with CNTY-308 in mid-2025."

Preclinical • Trial status • Immunology • Lupus Nephritis • Myositis • Systemic Lupus Erythematosus • Systemic Sclerosis